It is worth noting that BRAF mutations have been identified in 50–60% of all metastatic melanomas, with about 80–90% of these mutations involving the substitution of valine for glutamine at amino acid 600 (V600E), which is associated with a poor overall prognosis [18, 19]. This evidence concerns the gene BRAF and metastatic melanoma.